Your session is about to expire
← Back to Search
MRTX849 + Cetuximab for Colorectal Cancer
This trial is testing a new drug, MRTX849, to see if it is better than chemotherapy at treating colorectal cancer that has a KRAS G12C mutation.
- Colorectal Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a Location
Who is running the clinical trial?
- You have already received a specific type of chemotherapy for advanced colorectal cancer, and your cancer has gotten worse.You have previously been treated with medication that targets the KRAS G12C mutation, such as AMG 510.You have received treatment with a medication called cetuximab or panitumumab in the past.
- Group 1: MRTX849 + Cetuximab
- Group 2: mFOLFOX6 or FOLFIRI
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are investigators still enrolling individuals for this research project?
"That is correct, the information available on clinicaltrials.gov demonstrates that this trial is currently opened to recruitment. The study was first posted on March 15th, 2021 and has been updated as recently as November 3rd, 2022. A total of 420 patients will be recruited from 100 different sites."
In how many different medical clinics is this clinical trial being run today?
"There are 100 enrolling patients for this trial at locations such as Memorial Sloan Kettering Cancer Center - New York in New York, SCRI Tennessee Oncologyr - New York in New York, SCRI Tennessee Oncology Nashville Centennial in Nashville, and Research Site in Jacksonville."
What are the goals of this research?
"The primary goals of this long-term study are to track the Overall Survival rate of patients. Additionally, researchers hope to gain insights into Objective Response Rate, Patient Reported Outcomes, and Duration of Response."
Which conditions does MRTX849 commonly address?
"MRTX849 is an effective treatment against rectal carcinoma, colorectal carcinoma, and ovarian cancer."
How many individuals have signed up to participate in this research project?
"That is accurate. The latest information on clinicaltrials.gov indicates that this study is currently seeking patients. This particular trial was initially posted on March 15th, 2021 and updated November 3rd, 2022. In total, 420 patients are needed across 100 sites."
What is the official government stance on MRTX849?
"MRTX849 safety is estimated to be a 3. This is based on the fact that it is a Phase 3 trial, meaning efficacy has been supported by some data and safety has been backed up by multiple rounds of research."
What are the most recent findings concerning MRTX849?
"There are currently 634 different clinical trials studying MRTX849 with 167 of them in Phase 3. Most of these experiments are conducted in Pittsburgh, although there are 29376 total locations where trials for MRTX849 take place."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
How responsive is this trial?
Average response time
- < 1 Day
Typically responds via
Most responsive sites:
- Inova Schar Cancer Institute: < 24 hours
Share this study with friends